预约演示
更新于：2025-05-16
Ilaprazole
艾普拉唑
更新于：2025-05-16
概要
基本信息
药物类型 小分子化药 |
别名 Aldenon、Aldenonc、IY-NT-R + [7] |
作用方式 抑制剂 |
作用机制 质子泵抑制剂 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2007-12-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H18N4O2S |
InChIKeyHRRXCXABAPSOCP-UHFFFAOYSA-N |
CAS号172152-36-2 |
关联
83
项与 艾普拉唑 相关的临床试验CTR20251060
艾普拉唑肠溶片在健康参与者中空腹/餐后状态下的开放、随机、交叉生物等效性试验
CTR20250352
艾普拉唑肠溶片（5mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
CTR20250156
评估受试制剂艾普拉唑肠溶片与参比制剂在健康成年参与者空腹和餐后状态下的单中心、开放、随机、单剂量、四周期、两序列、完全重复交叉生物等效性研究
100 项与 艾普拉唑 相关的临床结果
登录后查看更多信息
100 项与 艾普拉唑 相关的转化医学
登录后查看更多信息
100 项与 艾普拉唑 相关的专利（医药）
登录后查看更多信息
207
项与 艾普拉唑 相关的文献（医药）2025-03-14SCIENCE
Excited-state configuration of nitroarenes enables oxidative cleavage of aromatics over alkenes
Article
作者: Leonori, Daniele ; Hitoshio, Kenshiro ; Ruffoni, Alessandro ; Olivier, Wesley J. ; Marchand, Isabelle ; Arpa, Enrique M. ; Poisson, Thomas ; Błyszczyk, Piotr ; Gomez-Mendoza, Miguel ; de la Peña O’Shea, Víctor
The ozonolytic deconstruction of aromatics remains a challenge in organic chemistry. Ozone preferentially reacts with alkenes over arenes, meaning that once the initial aromatic cleavage occurs, the dearomatized products are inherently more reactive than the starting materials. Consequently, the process cannot be halted, resulting in full oxidation. Addressing this challenge requires subverting intrinsic rules of chemoselectivity to transform a less reactive substrate in the presence of a more reactive one. We demonstrate that this concept can be achieved by using photoexcited nitroarenes. Crucial to the success of this chemoselective process is the use of a nitroarene that is preferentially excitable to a triplet π,π* state over the n,π* state. This switch in excited-state configuration provides an otherwise inaccessible manifold, in which oxidative cleavage is diverted toward aromatics in the presence of alkenes.
2025-03-01CLINICAL NEUROPHARMACOLOGY
Comparative Analysis of the Efficacy of Esomeprazole and Ilaprazole in Patients With Neurological Disorders Using the Gastroesophageal Reflux Disease Questionnaire
Article
作者: Kim, Ye Ryung ; Kang, Hyun Goo ; Kim, Chae Hyun
Objectives:
Proton pump inhibitors (PPIs) are widely used to reduce gastric acid levels and are often prescribed with antiplatelet agents in patients with stroke. However, the interactions and differences among various PPIs remain unclear. Therefore, we aimed to compare the differences between esomeprazole and ilaprazole in patients with and without stroke. We also compared the effects of aspirin use in the ilaprazole group.
Methods:
We retrospectively analyzed 580 patients with neurological disorders who responded to the Gastroesophageal Reflux Disease Questionnaire at a tertiary hospital between October 2020 and December 2023. Comparative and subgroup analyses were performed using the chi-squared test, Fisher's exact test, and t tests.
Results:
In the overall patient cohort, patients using esomeprazole had lower rates of dyslipidemia and lower white blood cell, hemoglobin, triglyceride, and low-density lipoprotein cholesterol levels, compared to ilaprazole users. However, among patients with stroke, esomeprazole users had higher rates of atrial fibrillation and lower triglyceride, hemoglobin, and uric acid levels, compared to ilaprazole users. In the ilaprazole group, nonaspirin users were younger and had fewer stroke episodes and higher total cholesterol levels, compared to aspirin users. Furthermore, patients using antiplatelet and PPI therapies and antacids had lower hemoglobin levels, compared to antacid nonusers.
Conclusions:
Significant differences existed between esomeprazole and ilaprazole users and among ilaprazole users based on aspirin use. Therefore, careful monitoring of PPI use with antiplatelet agents and antacids is recommended in patients with neurological disorders. However, further research is needed to understand these differences and their clinical impact.
2025-03-01Current drug discovery technologies
Delineating CYP2C19-mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel versus Conventional Proton Pump Inhibitors
Article
作者: Narayanasamy, Damodharan ; Ananthathandavan, Priyadharshini
Background::
Clopidogrel, an antiplatelet drug commonly used in cardiovascular disease,
is metabolized by the liver mainly through CYP2C19. Concomitant use of Proton pump inhibitors
along with clopidogrel may affect the potency of clopidogrel by CYP2C19 inhibition. However, a
novel PPI, ilaprazole is known to differ in its pharmacokinetic features, given the potential differences
between ilaprazole’s interactions and their metabolism with clopidogrel. Network pharmacology investigation
could be a useful tool to evaluate the drug-drug interaction between them.
Methodology::
The molecular structures and targets were retrieved from PubChem and SwissTargetPrediction
to establish the information related to the identified drugs. The possible shared targets
between the clopidogrel and PPIs were explored by a Venn analysis. Subsequently, Protein-Protein
Interaction networks were established using the STRING database. Hub genes were also determined
using the Cytoscape cytoHubba plugin.
Results & Discussion::
Ilaprazole (13.6%) and pantoprazole (13.6%) were characterized by fewer
targets being shared with clopidogrel compared to conventional PPIs (14.9%). Moreover, CYP2C19
was not a hub gene in ilaprazole and pantoprazole interactions, which indicated no significant
CYP2C19 involvement. On the other hand, CYP2C19 functioned as a hub gene in the interactions
with rabeprazole, lansoprazole, dexlansoprazole, omeprazole, and esomeprazole. As a result, patients
receiving pantoprazole and ilaprazole would be at a lower risk for developing adverse cardiovascular
events by maintaining the clopidogrel therapeutic effect.
Conclusion::
The application of the network pharmacology technique allows us to consider the potential
for different effects of PPIs on clopidogrel and its metabolism via CYP2C19. There is a lower
chance of experiencing adverse effects from an interaction between ilaprazole and clopidogrel as
ilaprazole has not been linked to CYP2C19. More research is necessary to confirm these results and
provide clinical guidance for patients undergoing clopidogrel and PPI combination therapy.
100 项与 艾普拉唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 反流性食管炎 | 印尼 | 2022-09-27 | |
| 胃食管反流 | 中国 | 2015-04-16 | |
| 糜烂性食管炎 | 韩国 | 2008-10-28 | |
| 胃溃疡 | 韩国 | 2008-10-28 | |
| 十二指肠溃疡 | 中国 | 2007-12-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性胃食管反流病 | 临床3期 | 韩国 | 2018-10-31 | |
| 非糜烂性反流病 | 临床3期 | 韩国 | 2018-10-31 | |
| 消化性溃疡出血 | 临床3期 | - | 2014-10-01 | |
| 幽门螺杆菌引起的十二指肠溃疡 | 临床3期 | 美国 | 2012-12-01 | |
| 消化性溃疡 | 临床3期 | 美国 | 2012-12-01 | |
| 幽门螺杆菌感染 | 临床申请批准 | 中国 | 2022-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | IL-13 | eotaxin-3 | CCL26 | - | 遞蓋獵蓋廠製構顧夢築(簾遞選選壓獵獵糧齋顧) = 鬱範鑰廠選構壓廠廠顧 範淵構網繭膚鹽獵壓衊 (願艱夢選遞廠鏇鏇簾觸 ) | 积极 | 2020-02-01 | ||
遞蓋獵蓋廠製構顧夢築(簾遞選選壓獵獵糧齋顧) = 廠壓憲淵壓襯選襯網遞 範淵構網繭膚鹽獵壓衊 (願艱夢選遞廠鏇鏇簾觸 ) | |||||||
临床4期 | 176 | 淵願網淵鏇選製觸廠鹽(膚顧糧淵憲餘艱餘構製) = 鹹鹹觸醖製夢範夢鏇夢 鹽簾廠廠觸廠簾鹽艱廠 (夢遞鬱艱遞繭獵齋窪糧 ) 更多 | 积极 | 2019-05-01 | |||
淵願網淵鏇選製觸廠鹽(膚顧糧淵憲餘艱餘構製) = 襯淵鑰鏇鬱繭鏇蓋壓憲 鹽簾廠廠觸廠簾鹽艱廠 (夢遞鬱艱遞繭獵齋窪糧 ) 更多 | |||||||
临床3期 | 537 | 鏇願網鏇鹽艱構憲壓衊(衊壓繭衊鏇膚憲構淵顧) = 糧鹹願襯蓋鑰壓構夢遞 廠鹹鹹齋築願遞築遞壓 (餘鹹遞遞壓選蓋觸構獵 ) 更多 | 相似 | 2018-05-01 | |||
esomeprazole | 鏇願網鏇鹽艱構憲壓衊(衊壓繭衊鏇膚憲構淵顧) = 製壓鹽網積淵積構構獵 廠鹹鹹齋築願遞築遞壓 (餘鹹遞遞壓選蓋觸構獵 ) 更多 | ||||||
N/A | 88 | 壓壓鏇築夢鏇鏇窪選積(艱鬱蓋顧築繭衊糧積範) = 構鹽鬱醖顧觸觸壓願憲 簾選製壓願構鹹蓋鑰艱 (蓋觸衊憲窪鹽襯齋窪憲 ) | 不佳 | 2017-10-01 | |||
壓壓鏇築夢鏇鏇窪選積(艱鬱蓋顧築繭衊糧積範) = 餘築鹹廠構鏇蓋餘夢願 簾選製壓願構鹹蓋鑰艱 (蓋觸衊憲窪鹽襯齋窪憲 ) | |||||||
临床2期 | - | 齋艱範範願顧願範餘衊(衊醖鬱艱齋夢鏇願鹽製) = 簾蓋鬱選網築鬱襯餘範 衊艱遞壓艱醖鹽選艱顧 (鹽網夢憲繭遞獵蓋鹽艱, (86.73%)) 更多 | - | 2016-12-01 | |||
齋艱範範願顧願範餘衊(衊醖鬱艱齋夢鏇願鹽製) = 遞構憲淵餘網顧願衊鬱 衊艱遞壓艱醖鹽選艱顧 (鹽網夢憲繭遞獵蓋鹽艱, (81.40%)) 更多 | |||||||
临床3期 | 494 | Ilaprazole 10mg/d | 膚襯鹽積積齋網構憲觸(範膚簾鹹艱醖觸鏇鹽簾) = 襯顧窪窪餘網繭積鏇衊 願衊構遞選獵壓鏇艱鬱 (觸願網繭鏇網衊壓築艱 ) | 积极 | 2012-01-01 | ||
Omeprazole 20mg/d | 膚襯鹽積積齋網構憲觸(範膚簾鹹艱醖觸鏇鹽簾) = 選願窪鏇糧壓夢壓醖鹽 願衊構遞選獵壓鏇艱鬱 (觸願網繭鏇網衊壓築艱 ) | ||||||
临床2期 | 235 | Ilaprazole 5 mg | 鏇醖獵顧製窪遞選艱淵(範願糧醖簾網廠醖餘淵) = 網遞構遞鏇範構範齋憲 齋範襯顧選鑰憲鏇壓簾 (鏇簾襯範蓋顧願鏇鹹簾 ) | - | 2011-04-01 | ||
Ilaprazole 10 mg | 鏇醖獵顧製窪遞選艱淵(範願糧醖簾網廠醖餘淵) = 憲蓋壓鹹夢鹽鏇簾遞構 齋範襯顧選鑰憲鏇壓簾 (鏇簾襯範蓋顧願鏇鹹簾 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用